Matches in SemOpenAlex for { <https://semopenalex.org/work/W181548351> ?p ?o ?g. }
- W181548351 endingPage "773" @default.
- W181548351 startingPage "765" @default.
- W181548351 abstract "To provide guidelines on use of anti-D prophylaxis to optimize prevention of rhesus (Rh) alloimmunization in Canadian women.Decreased incidence of Rh alloimmunization and minimized practice variation with regards to immunoprophylaxis strategies.The Cochrane Library and MEDLINE were searched for English-language articles from 1968 to 2001, relating to the prevention of Rh alloimmunization. Search terms included: Rho(D) immune globulin, Rh iso- or allo-immunization, anti-D, anti-Rh, WinRho, Rhogam, and pregnancy. Additional publications were identified from the bibliographies of these articles. All study types were reviewed. Randomized controlled trials were considered evidence of highest quality, followed by cohort studies. Key individual studies on which the principal recommendations are based are referenced. Supporting data for each recommendation is briefly summarized with evaluative comments and referenced.The evidence collected was reviewed by the Maternal-Fetal Medicine and Genetics Committees of the Society of Obstetricians and Gynaecologists of Canada (SOGC) and quantified using the Evaluation of Evidence guidelines developed by the Canadian Task Force on the Periodic Health Exam.1. Anti-D Ig 300 microg IM or IV should be given within 72 hours of delivery to a postpartum nonsensitized Rh-negative woman delivering an Rh-positive infant. Additional anti-D Ig may be required for fetomaternal hemorrhage (FMH) greater than 15 mL of fetal red blood cells (about 30 mL of fetal blood). Alternatively, anti-D Ig 120 microg IM or IV may be given within 72 hours of delivery, with testing and additional anti-D Ig given for FMH over 6 mL of fetal red blood cells (12 mL fetal blood). (I-A) 2. If anti-D is not given within 72 hours of delivery or other potentially sensitizing event, anti-D should be given as soon as the need is recognized, for up to 28 days after delivery or other potentially sensitizing event. (III-B) 3. There is poor evidence regarding inclusion or exclusion of routine testing for postpartum FMH, as the cost-benefit of such testing in Rh mothers at risk has not been determined. (III-C) 4. Anti-D Ig 300 microg should be given routinely to all Rh-negative nonsensitized women at 28 weeks' gestation when fetal blood type is unknown or known to be Rh-positive. Alternatively, 2 doses of 100-120 microg may be given (120 microg being the lowest currently available dose in Canada): one at 28 weeks and one at 34 weeks. (I-A) 5. All pregnant women (D-negative or D-positive) should be typed and screened for alloantibodies with an indirect antiglobulin test at the first prenatal visit and again at 28 weeks. (III-C) 6. When paternity is certain, Rh testing of the baby's father may be offered to all Rh-negative pregnant women to eliminate unnecessary blood product administration. (III-C) 7. A woman with weak D (also known as Du-positive) should not receive anti-D. (III-D) 8. A repeat antepartum dose of Rh immune globulin is generally not required at 40 weeks, provided that the antepartum injection was given no earlier than 28 weeks' gestation. (III-C) 9. After miscarriage or threatened abortion or induced abortion during the first 12 weeks of gestation, nonsensitized D-negative women should be given a minimum anti-D of 120 microg. After 12 weeks' gestation, they should be given 300 microg. (II-3B) 10. At abortion, blood type and antibody screen should be done unless results of blood type and antibody screen during the pregnancy are available, in which case antibody screening need not be repeated. (III-B) 11. Anti-D should be given to nonsensitized D-negative women following ectopic pregnancy. A minimum of 120 microg should be given before 12 weeks' gestation and 300 microg after 12 weeks' gestation. (III-B) 12. Anti-D should be given to nonsensitized D-negative women following molar pregnancy because of the possibility of partial mole. Anti-D may be withheld if the diagnosis of complete mole is certain. (III-B) 13. At amniocentesis, anti-D 300 microg should be given to nonsensitized D-negativeesis, anti-D 300 microg should be given to nonsensitized D-negative women. (II-3B) 14. Anti-D should be given to nonsensitized D-negative women following chorionic villous sampling, at a minimum dose of 120 microg during the first 12 weeks' gestation, and at a dose of 300 microg after 12 weeks' gestation. (II-B) 15. Following cordocentesis, anti-D Ig 300 microg should be given to nonsensitized D-negative women. (II-3B) 16. Quantitative testing for FMH may be considered following events potentially associated with placental trauma and disruption of the fetomaternal interface (e.g., placental abruption, blunt trauma to the abdomen, cordocentesis, placenta previa with bleeding). There is a substantial risk of FMH over 30 mL with such events, especially with blunt trauma to the abdomen. (III-B) 17. Anti-D 120 microg or 300 microg is recommended in association with testing to quantitate FMH following conditions potentially associated with placental trauma and disruption of the fetomaternal interface (e.g., placental abruption, external cephalic version, blunt trauma to the abdomen, placenta previa with bleeding). If FMH is in excess of the amount covered by the dose given (6 mL or 15 mL fetal RBC), 10 microg additional anti-D should be given for every additional 0.5 mL fetal red blood cells. There is a risk of excess FMH, especially when there has been blunt trauma to the abdomen. (III-B) 18. Verbal or written informed consent must be obtained prior to administration of the blood product Rh immune globulin. (III-C) VALIDATION: These guidelines have been reviewed by the Maternal-Fetal Medicine Committee and the Genetics Committee, with input from the Rh Program of Nova Scotia. Final approval has been given by the Executive and Council of the Society of Obstetricians and Gynaecologists of Canada." @default.
- W181548351 created "2016-06-24" @default.
- W181548351 date "2003-09-01" @default.
- W181548351 modified "2023-10-16" @default.
- W181548351 title "Prevention of Rh Alloimmunization" @default.
- W181548351 cites W146275532 @default.
- W181548351 cites W1868283005 @default.
- W181548351 cites W1970535226 @default.
- W181548351 cites W1979498865 @default.
- W181548351 cites W1981731644 @default.
- W181548351 cites W1982248245 @default.
- W181548351 cites W1987690973 @default.
- W181548351 cites W1991421499 @default.
- W181548351 cites W1994607699 @default.
- W181548351 cites W1995147685 @default.
- W181548351 cites W1999613570 @default.
- W181548351 cites W2007013428 @default.
- W181548351 cites W2022738437 @default.
- W181548351 cites W2029942414 @default.
- W181548351 cites W2032695034 @default.
- W181548351 cites W2033795091 @default.
- W181548351 cites W2034130308 @default.
- W181548351 cites W2049131154 @default.
- W181548351 cites W2060522709 @default.
- W181548351 cites W2066123775 @default.
- W181548351 cites W2070284893 @default.
- W181548351 cites W2077999988 @default.
- W181548351 cites W2090756175 @default.
- W181548351 cites W2094364091 @default.
- W181548351 cites W2113697441 @default.
- W181548351 cites W2128882976 @default.
- W181548351 cites W2141813796 @default.
- W181548351 cites W2145588654 @default.
- W181548351 cites W2161711976 @default.
- W181548351 cites W2163158112 @default.
- W181548351 cites W2274546328 @default.
- W181548351 cites W2314832209 @default.
- W181548351 cites W2398697215 @default.
- W181548351 cites W2786617866 @default.
- W181548351 cites W2915008295 @default.
- W181548351 cites W2965880213 @default.
- W181548351 cites W4367435877 @default.
- W181548351 doi "https://doi.org/10.1016/s1701-2163(16)31006-4" @default.
- W181548351 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12970812" @default.
- W181548351 hasPublicationYear "2003" @default.
- W181548351 type Work @default.
- W181548351 sameAs 181548351 @default.
- W181548351 citedByCount "73" @default.
- W181548351 countsByYear W1815483512012 @default.
- W181548351 countsByYear W1815483512013 @default.
- W181548351 countsByYear W1815483512014 @default.
- W181548351 countsByYear W1815483512015 @default.
- W181548351 countsByYear W1815483512016 @default.
- W181548351 countsByYear W1815483512017 @default.
- W181548351 countsByYear W1815483512018 @default.
- W181548351 countsByYear W1815483512019 @default.
- W181548351 countsByYear W1815483512020 @default.
- W181548351 countsByYear W1815483512021 @default.
- W181548351 countsByYear W1815483512022 @default.
- W181548351 crossrefType "journal-article" @default.
- W181548351 hasConcept C120665830 @default.
- W181548351 hasConcept C121332964 @default.
- W181548351 hasConcept C121857725 @default.
- W181548351 hasConcept C126322002 @default.
- W181548351 hasConcept C131872663 @default.
- W181548351 hasConcept C159654299 @default.
- W181548351 hasConcept C168563851 @default.
- W181548351 hasConcept C17744445 @default.
- W181548351 hasConcept C187212893 @default.
- W181548351 hasConcept C199539241 @default.
- W181548351 hasConcept C203014093 @default.
- W181548351 hasConcept C2776162027 @default.
- W181548351 hasConcept C2776478404 @default.
- W181548351 hasConcept C2779234561 @default.
- W181548351 hasConcept C2779473830 @default.
- W181548351 hasConcept C2780801004 @default.
- W181548351 hasConcept C29456083 @default.
- W181548351 hasConcept C3018664633 @default.
- W181548351 hasConcept C54355233 @default.
- W181548351 hasConcept C61511704 @default.
- W181548351 hasConcept C71924100 @default.
- W181548351 hasConcept C86803240 @default.
- W181548351 hasConceptScore W181548351C120665830 @default.
- W181548351 hasConceptScore W181548351C121332964 @default.
- W181548351 hasConceptScore W181548351C121857725 @default.
- W181548351 hasConceptScore W181548351C126322002 @default.
- W181548351 hasConceptScore W181548351C131872663 @default.
- W181548351 hasConceptScore W181548351C159654299 @default.
- W181548351 hasConceptScore W181548351C168563851 @default.
- W181548351 hasConceptScore W181548351C17744445 @default.
- W181548351 hasConceptScore W181548351C187212893 @default.
- W181548351 hasConceptScore W181548351C199539241 @default.
- W181548351 hasConceptScore W181548351C203014093 @default.
- W181548351 hasConceptScore W181548351C2776162027 @default.
- W181548351 hasConceptScore W181548351C2776478404 @default.
- W181548351 hasConceptScore W181548351C2779234561 @default.
- W181548351 hasConceptScore W181548351C2779473830 @default.
- W181548351 hasConceptScore W181548351C2780801004 @default.